

PROGRESS

In The Management Of Cystic Fibrosis



creon[®] 
pancreatin

RIGHT ON TARGET – RIGHT FROM THE START

Prescribing Information – Presentation: Brown-yellow capsules containing enteric coated granules of pancreatin equivalent to: 9,000 BP units of amylase, 8,000 BP units of lipase, 210 BP units of protease. Available in packs of 100. Basic NHS price £13.33. **Indication:** Pancreatic exocrine insufficiency. **Dosage and administration:** Adults and children: Initially one or two capsules with meals, then adjust according to response. The capsules can be swallowed whole, or for ease of administration they may be opened and the granules taken with fluid or soft food, but without chewing. If the granules are mixed with food, it is important that they are taken immediately, otherwise dissolution of the enteric coating may result.

Contra-indications, Warnings, etc: Contra-indications: Substitution with pancreatic enzymes is contra-indicated in the early stages of acute pancreatitis. **Warnings:** Use in pregnancy: There is inadequate evidence of safety in use during pregnancy. The product is of porcine origin. Rarely cases of hyper-uricosuria and hyper-uricaemia have been reported with high doses of pancreatin. Overdosage could precipitate meconium ileus equivalent. Perianal irritation could occur, and, rarely, inflammation when large doses are used. **Product Licence Number:** 5727/0001. **Name and address of Licence Holder:** Kali Chemie Pharma GmbH, Postfach 220, D-3000, Hannover 1, West Germany.

duphar Further information is available from:
Duphar Laboratories Limited, Gaters Hill, West End, Southampton SO3 3JD. Tel: 0703 472281.

CRA4/PE1/1/89




Making sure Ventolin gets through to the younger generation



VENTODISKS

(Salbutamol BP)



Ventodisks (Salbutamol BP). **Abridged Prescribing Information** (Please refer to full data sheet before prescribing.) **Uses:** Treatment and prophylaxis of acute and chronic bronchospasm. **Dosage and administration:** *Adults:* 400 micrograms as single dose or three to four times daily. *Children:* 200 micrograms as single dose or three to four times daily. **Contra-indications:** Threatened abortion during first or second trimester. Hypersensitivity. **Precautions:** If previously effective dose lasts less than three hours, seek medical advice. Caution in patients with thyrotoxicosis. Avoid use with non-selective beta-blockers. Hypokalaemia may occur, particularly in acute severe asthma. It may be potentiated by xanthine derivatives, steroids, diuretics and hypoxia. Serum potassium levels should be monitored in such situations. **Pregnancy:** Avoid unnecessary use during early pregnancy. Only consider if expected benefit outweighs possible risks. **Lactation:** Salbutamol likely to

be secreted in breast milk. Effect on neonate unknown. Balance risks against benefits. **Side effects:** Mild tremor, headache occur rarely. Very rarely — transient muscle cramps and hypersensitivity reactions. Potentially serious hypokalaemia may result from B_2 -agonist therapy. Paradoxical bronchospasm could occur — substitute alternative therapy. **Presentation and Basic NHS cost:** Pack of 14 Ventodisks each containing 8 x 200 micrograms Salbutamol BP (as sulphate) — light blue or 8 x 400 micrograms Salbutamol BP (as sulphate) — dark blue, together with a Ventolin Diskhaler. For inhalation. £7.11 and £12.02. Refill pack of 14 x 8 Ventodisks only, 200 micrograms, £6.54; 400 micrograms, £11.45. **Product licence numbers:** Ventodisks 200 micrograms 0045/0134, Ventodisks 400 micrograms 0045/0135.



ALLEN & HANBURYS

Further information is available on request from: Allen & Hanburys Limited, Stockley Park West, Uxbridge, Middlesex UB11 1BT
Ventodisks should only be used with a Ventolin Diskhaler. Diskhaler, Ventodisks and Ventolin are trade marks



THE VERY PALATABLE FACTS ABOUT PREJOMIN.

Prejomin is the prescribable protein hydrolysate that's completely free from lactose and milk protein residues.

So it will suit a far greater number of your hypersensitive patients.


But just as important, its taste will suit them as well.

And with babies or infants, a hypoallergenic formula can only be as good as it tastes.

The Prejomin combination of nutrients has proved itself eminently acceptable to them again and again.

While its proven efficacy will make it equally acceptable to you.

Prejomin. The palatable solution to the dietetic management of chronic diarrhoea and food intolerances.



milupa[®]
Experts in
Infant Nutrition

Some infants are ahead of their time.



Fortunately, so are we.

Cow & Gate has been looking after the nutritional needs of infants for over 90 years. During that time, we've created the widest range of formulas and foods for normal infants and those with very special needs.

The low birth weight baby is one of them.

Our Low Birth Weight Formula was specially created to provide higher energy and nutrient levels, at a lower volume than might otherwise be obtained from breastmilk or standard infant formula - an important consideration in the prevention of problems associated with immature digestive systems.



This formulation was one of the first designed to meet the guidelines set out by ESPGAN, the European Society of Paediatric Gastroenterology and Nutrition.

What's more, Cow & Gate Low Birth Weight Formula achieves good calcium retention and still offers the lowest osmolality of any low birth weight formula available today.

Cow & Gate Low Birth Weight Formula. Well-absorbed. Proven well-tolerated.


And just one of an ever increasing range of infant formulas and foods from a specialist ahead of its time.

Extra nourishment when it's needed most

**Cow
& Gate**

Convenient 60ml size
means less waste

A breakthrough in seizure control...




..in uncontrolled epilepsy
a >50% reduction in seizure
frequency in approximately
50% of patients⁽¹⁾

- No therapeutically significant drug interactions with other anti-convulsants^{(2-5)*}
- Flexible dosing - once or twice daily



SABRIL[®]
VIGABATRIN

Specific GABA-transaminase inhibition
for uncontrolled epilepsy



**Decreases of about 20% in plasma phenytoin levels have been reported but these are unlikely to be of therapeutic significance.*

Merrell Dow Pharmaceuticals Limited, Lakeside House, Stockley Park, Uxbridge, Middlesex UB11 1BE
TRADEMARKS Sabril, Merrell Dow.

MERRELL

DOW

Abridged Prescribing Information
SABRIL Tablets ▼

Presentation: White tablets with a breakline marked SABRIL, each containing 500mg vigabatrin.

Uses:

Indications: Treatment of epilepsy not controlled by other antiepileptic drugs.

Dosage and Administration: Oral administration once or twice daily added to the patient's current therapeutic regimen.

Adults: Recommended starting dose 2g/day. Increased or decreased in 0.5g or 1.0g increments depending upon clinical response and tolerability. Maximum 4g/day. There is no direct correlation between plasma concentration and efficacy.

Children: Recommended starting dose 1g/day in ages 3-9 years and 2g/day if older.

Elderly: Consider dose reduction in patients with impaired renal function.

Contra-indications, Precautions, Warnings etc.:

Use in pregnancy and lactation: Contra-indicated.

Precautions: Abrupt withdrawal may lead to rebound seizures. Caution in patients with history of psychosis or behavioural problems. Caution in elderly patients, particularly creatinine clearance below 60ml/min. Reduce dose and monitor closely for adverse events.

Warnings: Vigabatrin causes intramyelinic oedema in the brain white matter tracts of animals but there is no evidence of this in man. However, monitor patients for neurological changes. See the full product data sheet.

Effects on driving ability: Drowsiness has been seen and patients should be warned.

Side-effects: Are mainly CNS related. Aggression and psychosis have been reported and a previous history of psychosis or a behavioural problem appears to be a predisposing factor. Other reported events: drowsiness and fatigue, dizziness, nervousness, irritability, depression, headache and less commonly confusion, memory disturbance and vision complaints; also weight gain and minor gastrointestinal side-effects. Also in children excitation and agitation. Some patients may experience an increase in seizure frequency with vigabatrin, particularly those with myoclonic seizures. Tests have not revealed evidence of neurotoxicity in humans. Lab data do not indicate renal or hepatic toxicity. Decreases in SGOT and SGPT have been observed. Chronic treatment may lead to a slight decrease in haemoglobin.

Drug Interactions: are unlikely. A gradual reduction of about 20% in plasma phenytoin concentration has been observed. No clinically significant interactions with carbamazepine, phenobarbitone or sodium valproate.

Legal Category: POM

Package Quantities: Blister strips of 10 in cartons of 100.

Product Licence Number: PL 4425/0098.

NHS Price: Pack of 100 tablets: £46.

Date of Preparation: December 1990

You must refer to the full prescribing information before administering Sabril. Further information including full product data sheet is available from the Licence Holder:

Merrell Dow Pharmaceuticals Ltd, Lakeside House, Stockley Park, Uxbridge, Middlesex UB11 1BE.

References

- Mumford JP, Br J Clin Pract 1988; 42 (Suppl 61): 7-9.
- Browne TR, et al. Neurology 1987; 37: 184-189.
- Tartara A, et al. Epilepsia 1986; 27: 717-723.
- Tassinari CA, et al. Arch Neurol 1987; 44: 907-910.
- Rimmer EM, Richens A. Lancet 1984; 1: 189-190.




Trademarks: Sabril, Merrell Dow.

**MERRELL
DOW**

Endotracheal tube	
Length (cm)	Internal diameter (mm)
18-21	7.5-8.0
18	7.0
17	6.5
16	6.0
15	5.5
14	5.0
13	4.5
12	4.0
10	3.5
	3.0-3.5

Paediatric resuscitation chart



Adrenaline (ml of 1/10 000) intravenous or endotracheal	0.5	1	2	3	4	5
Atropine (mg) intravenous or endotracheal	0.1	0.2	0.4	0.6	0.6	0.6
Bicarbonate (ml of 8.4%) intravenous	5	10	20	30	40	50
Calcium chloride (mmol)* intravenous	1	2	4	6	8	10
Diazepam (mg) intravenous	1.25	2.5	5	7.5	10	10
	2.5	5	10	—	—	—
Glucose (ml of 50%) intravenous	10	20	40	60	80	100
Lignocaine (mg) intravenous or endotracheal	5	10	20	30	40	50
Salbutamol (µg) intravenous	25	50	100	150	200	250
Initial DC defibrillation (J)	10	20	40	60	80	100
Initial fluid infusion in hypovolaemic shock (ml)	50	100	200	300	400	500

* One millilitre calcium chloride 1 mmol/ml = 1.5 ml calcium chloride 10% = 4.5 ml calcium gluconate 10%

A child is dying: what do you do?

Resuscitating children is different from resuscitating adults—and more difficult. Because cardiorespiratory arrest in children is uncommon each doctor's experience of handling it is limited, and there is a tendency to forget the recommended drug doses; also, because children come in so many different sizes it is hard to judge the correct dose, especially if you do not know the child's weight. Yet delay or inaccuracy in treatment might be fatal. **The Paediatric Resuscitation Chart**, devised by Dr Peter Oakley and based on the guidelines of the Resuscitation Council (UK), gives you at a glance the essential information for making rapid and accurate decisions. The chart is available as an A2 size poster or a pocket sized postcard.

Poster: UK £3.50; Abroad £4.50 including packing and postage, by air abroad.

Single copies of a postcard version of the chart are available, free of charge, on receipt of an A5 stamped addressed envelope (16cm x 24cm; 6in x 9in). Bulk orders please write to the Book Department.

Credit cards are accepted: ACCESS, VISA, AMERICAN EXPRESS (please give full details)

BMJ

BRITISH MEDICAL JOURNAL, BMA HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR

INSTITUTE OF CHILD HEALTH
(University of London)

Advanced Paediatric Neurology:
Infections and the Nervous System

10-12 June 1991

This course will focus on recent advances in infections of the nervous system in the paediatric age group. It will include contributions on epidemiology, pathology, clinical and laboratory aspects. It is intended for Paediatric Neurologists.

Fee: £165.00 (including lunch and refreshments).

For full programme and registration form please contact:

Short Courses Office
Institute of Child Health
30 Guilford Street
London
WC1N 1EH
Tel: 071-829 8692

Calculate with confidence:

Confidence Interval Analysis (CIA) is a computer program that takes the sweat out of calculating confidence intervals. Devised by Martin Gardner, professor of medical statistics, MRC Environmental Epidemiology Unit, University of Southampton, the IBM compatible program is menu driven with easy access to each chapter and to the method required within each chapter. Topics covered include calculating confidence intervals for:

- means and their differences
- proportions and their differences
- regression and correlation
- non-parametric analyses

For each method relevant intermediate statistics and the required confidence interval are produced on the screen. Complete with its own manual, the program (available on 5¼" or 3½" disk) may also be used in conjunction with the book *Statistics with Confidence*, which provides numerous worked examples.

£65.00. Educational establishments, research institutes, and the NHS — £45.95. Prices include VAT in the UK and air mail despatch abroad

★UK £7.95; Abroad £9.50

BMA members UK £7.45; Abroad £9.00

Please enclose payment with order (stating size of disk required), or send us full details of your MASTERCARD, VISA or AMERICAN EXPRESS credit card.

Order from: BRITISH MEDICAL JOURNAL
PO Box 295, London WC1H 9TE

CURRENT PAEDIATRICS

New from
Churchill Livingstone
First issue now available



Chairman *D Hull*
Executive Editor *R Wilson*
Editorial Committee *M Dillon, D Hall*
and *M Levene*

Current Paediatrics will provide busy clinicians with educational reviews designed to keep them up to date in paediatrics and child health. Over a 3-year cycle of 12 quarterly issues, the journal will cover most of the relevant topics. The emphasis of the journal will be on clear, concise presentations of information of direct clinical relevance to both hospital and community-based paediatricians.

Current Paediatrics will be invaluable to MRCP and DCH candidates *as well as for* fully qualified paediatricians.

Current Paediatrics will keep you up to date on delivery of care, technical procedures, investigations, innovations, legal matters and basic science.

The first issue includes...

Diagnosis and management of the acute abdomen, Management of chronic constipation, Vomiting, Acute upper airway obstruction, Chronic upper airway obstruction, The management of asthma, Occult lesions of the spine, Post neonatal infant mortality, Prophylaxis of meningitis in childhood, Physiotherapy in neurological disorders, Measurement of intracranial pressure, Making health education work.

Subscription Information

ISSN 0957-5839 Volume 1 First issue March 1991
Trainee UK £25.00 USA \$46.50 Other £29.00
Individual UK £35.00 USA \$65.00 Other £40.00
Institutional UK £89.00 USA \$164.00 Other £102.50

If you would like a free sample copy of the first issue or would like to subscribe, please write to
Sales Promotion Department
Churchill Livingstone Medical Journals
Robert Stevenson House, Baxter's Place,
Edinburgh EH1 3AF, UK

Churchill Livingstone

MONATS **KINDER** SCHRIFT **HEILKUNDE**

139. Band Heft 3
März 1991

Organ der
Deutschen Gesellschaft
für Kinderheilkunde

Thema des Monats

Mukopolysaccharidosen
Editorial 119
M. Beck
Mukopolysaccharidosen:
Nosologie — Klinik —
Therapieansätze 120

Pädiatrie aktuell

Enterokokken als
Sepsisursache bei Neu-
und Frühgeborenen
Senkt die bereits vor
der Schwangerschaft
einsetzende Ver-
besserung der Stoff-
wechseleinstellung
insulinabhängiger Dia-
betikerinnen das Risiko
der Geburt fehlgebildeter
Kinder?
Vergleich unterschiedlicher
Immunglobulindosen bei der
Behandlung des
Kawasaki-Syndroms 128

Was hat das Kind?

Trainingsprogramm für die
Weiterbildung zum Kinder-
arzt 129

Klinik und Forschung

S. Liptay, C. P. Bauer,
A. Grübl, R. Franz,
P. Emmrich
Atopieentwicklung in der
frühen Kindheit —
Prädisponierende Fak-
toren 130
Ch. Pabelick, B. Koletzko
Befunde bei Neugeborenen
nierentransplantiert
Mütter 136
W. Klapsch, Ch. Tschauner,
R. Graf
Kostendämpfung durch die
generelle sonographische
Hüftvorsorgeunter-
suchung 141
H. Bode, R. Bubl
Hirndurchblutung bei zere-
bralen Residualschäden.
Eine Doppler-sonographische
Studie 144

Der interessante Fall

U. Bertram, G. Hüls,
W. Padberg, J. Turski,
M. Altmannsberger
Entzündlich fibroider Polyp
des Magens als ungewöh-
nliche Differentialdiagnose
eines Oberbauchtumors 151
I. D. Mutz, R. Stering
Konnatales Neuroblastom
und Plazenta-
metastasen 154
W. Sperl, H. Fischer,
J. Hager
Chilaiditi's Koloninterposition
bei einer Patientin mit Rett-
Syndrom 157
B. Sommer, H. L. Spohr
GM₁-Gangliosidose Variante
O (M. Sandhoff): Verdachts-
diagnose einer Speicher-
krankheit durch
Ultraschall 160

Wußten Sie schon?

Aus der Klinik —
für die Klinik
G. Conrad, A. Ch. Ludwig,
F. Daschner
Sinnvolle und umwelt-
schonende Desinfektion in
der Pädiatrie 163
G. Conrad, M. Scherrer,
F. Daschner
Vorschläge zur Abfallvermei-
dung und Umweltschutz in
der Kinderklinik und
kinderärztlichen Praxis 168

Was hat das Kind?

Auflösung und
Kommentar des
Trainingsprogramms 156

Tagesgeschichte 170
Tagungskalender 170

Abstracts der 21. Jahres-
tagung der Arbeitsgemein-
schaft für Pädiatrische
Nephrologie, 7.—9. 3. 1991
in Essen 174

Abstracts der 6. Jahres-
tagung der Gesellschaft für
Pädiatrische Gastroentero-
logie und Ernährung,
1.—4. 5. 1991
in Goldegg 189



Springer-Verlag
Berlin Heidelberg New York
London Paris Tokyo
Hong Kong Barcelona Budapest

Annual subscription: DM 298,- plus postage

European Journal of

Pediatrics

Incorporating

Acta Paediatrica Belgica

and

Helvetica Paediatrica Acta

Volume 150 No. 4 1991

Jürgen Spranger: on the occasion
of his 60th birthday 219

Review

Balloon occlusion aortography
T. Ino, S. Shimazaki, K. Nishimoto,
K. Akimoto, M. Iwahara, K. Yabuta,
M. Watanabe, A. Tanaka, Y. Hosoda
220

Hematology/Oncology

**Diffuse infantile haemangiomatosis:
clinicopathological features and
management problems in five fatal
cases**
R. W. Byard, P. E. Burrows, T. Izakawa,
M. M. Silver 224

**Mega-dose intravenous
methylprednisone for the treatment
of onyala: a case report**
Ş. Özsoylu, G. Ertürk 228

Immunology/Allergology

**Lymphocyte subsets in whole blood
and isolated mononuclear leucocytes
of healthy infants and children**
N. Remy, M. Oberreit, G. Thoenes,
U. Wahn 230

**IgG2 deficiency in children with human
immunodeficiency virus infection**
P. Bartmann, I. Grosch-Wörner, V. Wahn,
B. H. Belohradsky 234

**Effects of short-term administration
of human chorionic gonadotropin on
immune functions in cryptorchid
children**
M. Maghnie, A. Valtorta, A. Moretta,
D. Larizza, M. A. Girani, F. Severi 238

**Severe pulmonary vascular occlusive
disease following bone marrow
transplantation in Omenn syndrome**
C. Brückmann, W. Lindner, R. Roos,
W. Permanetter, R. J. Haas,
S. G. Haworth, B. H. Belohradsky 242

Medical genetics

**New observations on midline defects:
Coincidence of anophthalmos,
microphthalmos and cryptophthalmos
with hypothalamic disorders**
J. R. Bierich, M. Christie, J. J. Heinrich,
A. S. Martinez 246

The Floating-Harbor syndrome
F. Majewski, H.-G. Lenard 250

**Cystic fibrosis and Helicobacter pylori
gastritis, megaloblastic anaemia,
subnormal mentality and minor
anomalies in two siblings: a new
syndrome?**
M. M. Lubani, Q. A. Al-Saleh, A. S. Teebi,
A. Moosa, M. H. Kalaoui 253

**Prenatal deletion detection in a
sporadic case of Duchenne muscular
dystrophy without genotype
information from the affected
individual**
F. Peinemann, M. Wagner, U. Franke,
M. Kulle, J. Reiss 256

Metabolic diseases

**Renal tubular dysfunction in
methylmalonic acidemia**
C. T. D'Angio, M. J. Dillon, J. V. Leonard
259

**Cystic fibrosis presenting with
recurrent vomiting and metabolic
alkalosis**
P. M. Mathew, J. A. Hamdan, H. Nazer
264

Neonatology

**Breast mild jaundice: natural history,
familial incidence and late
neurodevelopmental outcome of the
infant**
E. Grunebaum, J. Amir, P. Merlob,
M. Mimouni, I. Varsano 267

**First day serum creatine kinase BB
isoenzyme in high-risk infants**
R. A. Primhak, E. Simmonds 271

**Clinical usefulness of high intensity
green light phototherapy in the
treatment of neonatal jaundice**
M. Amato, D. Inaebnit 274

**Early onset neonatal sepsis with
Campylobacter jejuni: a case report**
R. Krishnaswamy, P. Sasidharan,
A. Rejjal, Y. Abu Osba 277

Nephrology

**Haemolytic uraemic syndrome in the
defined population of Northeast of
Scotland**
I. A. Abu-Arafeh, P. J. Smail,
G. G. Youngson, I. A. Auchterlonie 279

Neuropediatrics

**Brain abscess in childhood –
long-term experiences**
C. Aebi, F. Kaufmann, U. B. Schaad 282

**Low arylsulphatase A activity and
choreoathetotic syndrome in three
siblings: differentiation of pseudo-
deficiency from metachromatic
leukodystrophy**
J. Kappler, R. W. E. Watts, E. Conzelmann,
D. A. Gibbs, P. Propping, V. Gieselmann
287

Letter to the editors

**The first prenatal diagnosis of
dihydropyrimidine dehydrogenase
deficiency**
C. Jakobs, F. Stellaard, L. M. E. Smit,
J. M. G. van Vugt, M. Duran, R. Berger,
P. Rovers 291

Abstracts

**27th Workshop for Pediatric Research
held at the Kinderklinik of the
Georg-August-University Göttingen,
28 February – 1 March 1991 292**

Indexed in *Current Contents*



Springer International

Subscription information

Volume 149 (12 issues) will appear in 1990. Information about obtaining back volumes and microform editions available upon request.

North America. Annual subscription rate: approx. US \$ 868.00 (single issue price approx. \$ 87.00), including carriage charges. Subscriptions are entered with prepayment only.

Orders should be addressed to:

Springer-Verlag New York Inc.
Service Center Secaucus
44 Hartz Way
Secaucus, NJ 07094, USA
Tel. (201) 348-4033
Telex 023125994
FAX (201) 348-4505

All other countries. Annual subscription rate: DM 1532.00 plus carriage charges; Federal Republic of Germany: DM 20.54 incl. value added tax; all other countries: DM 39.00 ex-

cept for the following countries to which SAL delivery (Surface Airmail Lifted) is mandatory: Japan DM 103.80, India DM 75.00, Australia/New Zealand DM 119.40. Airmail delivery to all other countries is available upon request. Volume price: DM 1532.00, single issue price: DM 153.20 plus carriage charges. Subscriptions can either be placed via a bookdealer or sent directly to:

Springer-Verlag
Heidelberger Platz 3, D-1000 Berlin 33
Tel. (0)30/8207-0, Telex 183319
FAX (0)30/8214091

“Days
to remember
... *all my life*”



Prescribing Information PenMix® 30/70 100iu/ml (Biphasic Isophane Insulin Injection 30/70), Human Insulin (pyr).
Indications: The treatment of insulin-requiring diabetics.
Dosage and Administration: The dosage is determined by the physician according to the needs of the patient. Given by subcutaneous injection and intended for use in the NovoPen and NovoPen II injection devices only. (See instructions for use of devices). Resuspend before use by agitating up and down.
Contraindications: Hypoglycaemia. **Precautions:** Injections of PenMix 30/70 should be followed by a meal within 30 minutes of administration. A dosage reduction may be required on transfer from bovine or mixed species insulin. Reduction of early warning symptoms of hypoglycaemia may be seen upon tightening control and has been reported by a few patients on transfer from animal source to human insulin. Beta blockers, MAOIs and alcohol may enhance hypoglycaemic effect of insulin. Corticosteroids, thyroid hormones, oral contraceptives may increase insulin requirements. **Use in pregnancy:** Insulin requirements usually fall during the first trimester and increase during second and third trimester. **Side-effects:** Lipodystrophy, insulin resistance and hyper-sensitivity are rarely reported with human insulin. **Product Licence Number and Basic NHS Price:** PL 4668/0020, 5x1.5ml cartridges £8.10. **Product Licence Holder:** Novo Nordisk A/S, Novo Alle, DK-2880 Bagsvaerd, Denmark. **Sole Distributor:** Farillon Limited, Ashton Road, Harold Hill, Romford, Essex RM3 8UE. **Further information is available on request from:** Novo Nordisk Pharmaceuticals Ltd., Novo Nordisk House, Broadfield Park, Brighton Road, Pease Pottage, Crawley, West Sussex RH11 9RT. Telephone: (0293) 613555. January 1991

* Registered trade mark of Novo Nordisk A/S

Free supplies of NovoPen II available on request
DIAL 100 AND ASK FOR FREEPHONE
NOVO NORDISK INSULIN

Leading the way in diabetes care




Novo Nordisk

For many patients with diabetes, convenience can matter just as much as control.

That is why PenMix 30/70 is such an appropriate choice for people of all ages.

PenMix 30/70 lets them get on with enjoying their lives without the fuss and bother of complex in-syringe insulin mixing and with the added convenience of NovoPen® II.



PenMix® 30/70

Human pre-mixed neutral and isophane insulin (pyr)

CONVENIENCE WITH CONTROL
ALL IN ONE EASY STEP